Abstract #518574: Ultrasensitive Structural Variant-based ctDNA detection of MRD in Colorectal Cancer – the CITCCA study
Prevalence and dynamics of circulating tumor DNA among patients with triple-negative breast cancer undergoing preoperative systemic therapy with or without immunotherapy
Neo-N: three-year event-free survival (EFS) and overall survival (OS) and ultrasensitive ctDNA and tumor infiltrating lymphocyte (TIL) dynamics in early triple-negative breast cancer (tnbc) treated with neoadjuvant carboplatin/paclitaxel and nivolumab
CATER-MRD: Capecitabine for Targeted Eradication of aRising ctDNA Molecular Residual Disease in ER+/HER2-negative Breast Cancer
CLAIRE: A Multicenter, Prospective Single-arm Phase II Study Evaluating Liquid Biopsy Guided Intensified Follow-up Surveillance in Patients with Intermediate to High-risk ER+/HER2-negative Early-stage Breast Cancer
Longitudinal ctDNA Tracking in Early and Recurrent Breast Cancer Using an Ultrasensitive Structural Variant-Based Assay: An Updated Analysis from the TRACER Study
NeoCircle: circulating tumor DNA (ctDNA) dynamics during neoadjuvant chemotherapy predicts survival in primary breast cancer
Detecting ctDNA using personalized structural variants to forecast recurrence in localized soft tissue sarcoma (STS)
Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer
